Symbols / AUPH
AUPH Chart
About
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.92B |
| Enterprise Value | 1.65B | Income | 77.84M | Sales | 265.81M |
| Book/sh | 2.77 | Cash/sh | 2.67 | Dividend Yield | — |
| Payout | 0.00% | Employees | 130 | IPO | — |
| P/E | 26.05 | Forward P/E | 15.60 | PEG | — |
| P/S | 7.24 | P/B | 5.26 | P/C | — |
| EV/EBITDA | 16.41 | EV/Sales | 6.21 | Quick Ratio | 5.02 |
| Current Ratio | 5.76 | Debt/Eq | 21.38 | LT Debt/Eq | — |
| EPS (ttm) | 0.56 | EPS next Y | 0.94 | EPS Growth | 130.00% |
| Revenue Growth | 8.40% | Earnings | 2026-02-26 | ROA | 9.41% |
| ROE | 20.65% | ROIC | — | Gross Margin | 80.16% |
| Oper. Margin | 40.49% | Profit Margin | 29.28% | Shs Outstand | 131.84M |
| Shs Float | 127.98M | Short Float | 7.61% | Short Ratio | 8.74 |
| Short Interest | — | 52W High | 16.54 | 52W Low | 6.55 |
| Beta | 1.54 | Avg Volume | 1.07M | Volume | 894.80K |
| Target Price | $16.67 | Recom | Buy | Prev Close | $14.83 |
| Price | $14.59 | Change | -1.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.67
Mean price target
2. Current target
$14.59
Latest analyst target
3. DCF / Fair value
$11.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.59
Low
$13.00
High
$21.00
Mean
$16.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-03 | down | Leerink Partners | Outperform → Market Perform | $16 |
| 2025-11-07 | up | Jefferies | Hold → Buy | $21 |
| 2025-11-05 | down | RBC Capital | Outperform → Sector Perform | $15 |
| 2025-08-01 | main | RBC Capital | Outperform → Outperform | $9 |
| 2024-09-16 | reit | Cantor Fitzgerald | Overweight → Overweight | $10 |
| 2024-09-09 | reit | Cantor Fitzgerald | Overweight → Overweight | $10 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-03-01 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-02-23 | main | Cantor Fitzgerald | Overweight → Overweight | $10 |
| 2024-02-22 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-02-16 | main | RBC Capital | Outperform → Outperform | $8 |
| 2023-09-22 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-08-07 | main | HC Wainwright& Co. | Buy → Buy | $15 |
| 2023-07-06 | reit | Cantor Fitzgerald | Overweight → Overweight | $15 |
| 2023-05-03 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2023-02-23 | reit | RBC Capital | — → Outperform | $11 |
| 2023-01-04 | main | RBC Capital | — → Outperform | $11 |
| 2022-11-07 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2022-11-04 | main | RBC Capital | — → Outperform | $10 |
| 2022-11-04 | down | Oppenheimer | Outperform → Perform | — |
- Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Mixed Recent Share Price Performance - simplywall.st ue, 24 Feb 2026 10
- Aurinia Pharmaceuticals sets Feb. 26 call on 2025 results, business progress - Stock Titan hu, 19 Feb 2026 11
- Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 24 Nov 2025 08
- Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH) - Seeking Alpha ue, 16 Dec 2025 08
- This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base - Investor's Business Daily Fri, 06 Feb 2026 08
- $AUPH stock is down 18% today. Here's what we see in our data. - Quiver Quantitative Mon, 29 Sep 2025 07
- The Technical Signals Behind (AUPH) That Institutions Follow - Stock Traders Daily Wed, 18 Feb 2026 05
- Investing in Aurinia Pharmaceuticals (NASDAQ:AUPH) a year ago would have delivered you a 80% gain - Yahoo Finance Sat, 07 Feb 2026 08
- Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating - Seeking Alpha Wed, 22 Oct 2025 07
- Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified - simplywall.st Sat, 08 Nov 2025 08
- Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates? - Yahoo Finance Fri, 07 Nov 2025 08
- Aruinia stock gains after Q3 earnings beat (AUPH:NASDAQ) - Seeking Alpha ue, 04 Nov 2025 08
- What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? - Yahoo Finance Fri, 05 Dec 2025 08
- Are Strong Financial Prospects The Force That Is Driving The Momentum In Aurinia Pharmaceuticals Inc.'s NASDAQ:AUPH) Stock? - simplywall.st Sun, 07 Sep 2025 07
- Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? - Yahoo Finance Wed, 10 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 49038 | — | — | Stock Award(Grant) at price 0.00 per share. | MILLER JOSEPH M | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 165384 | — | — | Stock Award(Grant) at price 0.00 per share. | GREENLEAF PETER S | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 54166 | — | — | Stock Award(Grant) at price 0.00 per share. | DONLEY MATTHEW MAXWELL | Chief Operating Officer | — | 2026-01-02 00:00:00 | D |
| 3 | 48558 | — | — | Stock Award(Grant) at price 0.00 per share. | ROBERTSON STEPHEN P | General Counsel | — | 2026-01-02 00:00:00 | D |
| 4 | 1300000 | 13590000.0 | — | Purchase at price 10.12 - 11.68 per share. | TANG KEVIN C | Director | — | 2025-08-05 00:00:00 | I |
| 5 | 20000 | 210000.0 | — | Sale at price 10.50 per share. | KEENAN GREG | Officer | — | 2025-08-01 00:00:00 | D |
| 6 | 8305 | 68350.0 | — | Sale at price 8.23 per share. | KEENAN GREG | Officer | — | 2025-03-07 00:00:00 | D |
| 7 | 1600000 | 12713126.0 | — | Purchase at price 7.85 - 8.09 per share. | TANG KEVIN C | Director | — | 2025-03-04 00:00:00 | I |
| 8 | 118013 | 939612.0 | — | Sale at price 7.92 - 8.00 per share. | MILLER JOSEPH M | Chief Financial Officer | — | 2025-03-04 00:00:00 | D |
| 9 | 360540 | 2871124.0 | — | Sale at price 7.92 - 8.00 per share. | GREENLEAF PETER S | Chief Executive Officer | — | 2025-03-04 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -5.27M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.23 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | 54.83M | -63.05M | -103.65M | -177.44M |
| TotalUnusualItems | -23.11M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -23.11M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | 5.75M | -78.02M | -108.18M | -180.97M |
| ReconciledDepreciation | 19.45M | 11.65M | 2.71M | 2.76M |
| ReconciledCostOfRevenue | 28.25M | 14.15M | 5.66M | 1.09M |
| EBITDA | 31.73M | -63.05M | -103.65M | -177.44M |
| EBIT | 12.28M | -74.69M | -106.35M | -180.21M |
| NetInterestIncome | 12.13M | 14.22M | 5.12M | 529.00K |
| InterestExpense | 4.83M | 2.77M | 0.00 | 0.00 |
| InterestIncome | 16.97M | 17.00M | 5.12M | 529.00K |
| NormalizedIncome | 23.59M | -78.02M | -108.18M | -180.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 5.75M | -78.02M | -108.18M | -180.97M |
| TotalExpenses | 216.71M | 267.20M | 245.50M | 226.34M |
| TotalOperatingIncomeAsReported | -4.69M | -91.69M | -111.47M | -180.74M |
| DilutedAverageShares | 146.19M | 143.24M | 141.91M | 129.37M |
| BasicAverageShares | 143.06M | 143.24M | 141.91M | 129.37M |
| DilutedEPS | 0.04 | -0.54 | -0.76 | -1.40 |
| BasicEPS | 0.04 | -0.54 | -0.76 | -1.40 |
| DilutedNIAvailtoComStockholders | 5.75M | -78.02M | -108.18M | -180.97M |
| NetIncomeCommonStockholders | 5.75M | -78.02M | -108.18M | -180.97M |
| NetIncome | 5.75M | -78.02M | -108.18M | -180.97M |
| NetIncomeIncludingNoncontrollingInterests | 5.75M | -78.02M | -108.18M | -180.97M |
| NetIncomeContinuousOperations | 5.75M | -78.02M | -108.18M | -180.97M |
| TaxProvision | 1.70M | 551.00K | 1.83M | 760.00K |
| PretaxIncome | 7.45M | -77.47M | -106.35M | -180.21M |
| OtherIncomeExpense | -23.11M | |||
| SpecialIncomeCharges | -23.11M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 23.11M | 0.00 | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 12.13M | 14.22M | 5.12M | 529.00K |
| InterestExpenseNonOperating | 4.83M | 2.77M | 0.00 | 0.00 |
| InterestIncomeNonOperating | 16.97M | 17.00M | 5.12M | 529.00K |
| OperatingIncome | 18.42M | -91.69M | -111.47M | -180.74M |
| OperatingExpense | 188.47M | 253.06M | 239.84M | 225.25M |
| OtherOperatingExpenses | -4.35M | 8.38M | -1.52M | 574.00K |
| DepreciationAmortizationDepletionIncomeStatement | 2.10M | |||
| DepreciationAndAmortizationInIncomeStatement | 2.10M | |||
| Amortization | 2.10M | |||
| AmortizationOfIntangiblesIncomeStatement | 2.10M | |||
| ResearchAndDevelopment | 20.79M | 49.64M | 44.99M | 51.14M |
| SellingGeneralAndAdministration | 172.03M | 195.04M | 196.37M | 173.54M |
| SellingAndMarketingExpense | 14.09M | 18.29M | ||
| GeneralAndAdministrativeExpense | 157.93M | 176.75M | 196.37M | 173.54M |
| OtherGandA | 53.06M | 57.47M | 196.37M | 173.54M |
| SalariesAndWages | 104.87M | 119.28M | 110.57M | 105.42M |
| GrossProfit | 206.88M | 161.37M | 128.37M | 44.51M |
| CostOfRevenue | 28.25M | 14.15M | 5.66M | 1.09M |
| TotalRevenue | 235.13M | 175.51M | 134.03M | 45.60M |
| OperatingRevenue | 235.13M | 175.51M | 134.03M | 45.60M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 140.88M | 143.83M | 142.27M | 141.60M |
| ShareIssued | 140.88M | 143.83M | 142.27M | 141.60M |
| TotalDebt | 79.37M | 97.61M | 8.09M | 8.74M |
| TangibleBookValue | 373.12M | 372.98M | 399.01M | 470.69M |
| InvestedCapital | 377.48M | 377.95M | 405.44M | 479.09M |
| WorkingCapital | 348.83M | 347.61M | 396.43M | 472.68M |
| NetTangibleAssets | 373.12M | 372.98M | 399.01M | 470.69M |
| CapitalLeaseObligations | 79.37M | 97.61M | 8.09M | 8.74M |
| CommonStockEquity | 377.48M | 377.95M | 405.44M | 479.09M |
| TotalCapitalization | 377.48M | 377.95M | 405.44M | 479.09M |
| TotalEquityGrossMinorityInterest | 377.48M | 377.95M | 405.44M | 479.09M |
| StockholdersEquity | 377.48M | 377.95M | 405.44M | 479.09M |
| GainsLossesNotAffectingRetainedEarnings | -647.00K | -730.00K | -1.06M | -852.00K |
| OtherEquityAdjustments | -647.00K | -730.00K | -1.06M | -852.00K |
| RetainedEarnings | -936.57M | -942.32M | -864.30M | -756.12M |
| AdditionalPaidInCapital | 127.00M | 120.79M | 85.49M | 59.01M |
| CapitalStock | 1.19B | 1.20B | 1.19B | 1.18B |
| CommonStock | 1.19B | 1.20B | 1.19B | 1.18B |
| TotalLiabilitiesNetMinorityInterest | 173.17M | 170.11M | 65.42M | 64.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 75.40M | 92.92M | 19.32M | 23.63M |
| OtherNonCurrentLiabilities | 11.11M | 3.31M | 12.17M | |
| DuetoRelatedPartiesNonCurrent | 7.60M | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 12.17M | 15.95M | ||
| LongTermDebtAndCapitalLeaseObligation | 64.30M | 82.01M | 7.15M | 7.68M |
| LongTermCapitalLeaseObligation | 64.30M | 82.01M | 7.15M | 7.68M |
| CurrentLiabilities | 97.76M | 77.19M | 46.11M | 40.65M |
| OtherCurrentLiabilities | 1.53M | 1.59M | 2.03M | 4.45M |
| CurrentDeferredLiabilities | 11.00M | 4.81M | 3.15M | 190.00K |
| CurrentDeferredRevenue | 11.00M | 4.81M | 3.15M | 190.00K |
| CurrentDebtAndCapitalLeaseObligation | 15.07M | 15.60M | 936.00K | 1.06M |
| CurrentCapitalLeaseObligation | 15.07M | 15.60M | 936.00K | 1.06M |
| PayablesAndAccruedExpenses | 70.16M | 55.19M | 39.99M | 34.95M |
| CurrentAccruedExpenses | 64.97M | 50.06M | 36.28M | 30.25M |
| Payables | 5.19M | 5.13M | 3.71M | 4.69M |
| DuetoRelatedPartiesCurrent | 800.00K | |||
| TotalTaxPayable | 667.00K | 625.00K | 814.00K | |
| IncomeTaxPayable | 667.00K | 625.00K | 814.00K | |
| AccountsPayable | 5.19M | 4.33M | 3.09M | 3.88M |
| TotalAssets | 550.64M | 548.06M | 470.86M | 543.37M |
| TotalNonCurrentAssets | 104.05M | 123.26M | 28.32M | 30.04M |
| OtherNonCurrentAssets | 823.00K | 1.52M | 13.34M | 11.84M |
| InvestmentsAndAdvances | 0.00 | 201.00K | 0.00 | 0.00 |
| GoodwillAndOtherIntangibleAssets | 4.36M | 4.98M | 6.42M | 8.40M |
| OtherIntangibleAssets | 4.36M | 4.98M | 6.42M | 8.40M |
| NetPPE | 98.87M | 116.57M | 8.56M | 9.80M |
| AccumulatedDepreciation | -2.53M | -1.91M | -1.46M | -836.00K |
| GrossPPE | 101.40M | 118.48M | 10.01M | 10.64M |
| Leases | 3.24M | 3.24M | 2.98M | 2.98M |
| ConstructionInProgress | 0.00 | 255.00K | 393.00K | |
| OtherProperties | 96.14M | 113.21M | 4.91M | 5.38M |
| MachineryFurnitureEquipment | 2.02M | 2.02M | 1.87M | 1.88M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 446.60M | 424.80M | 442.54M | 513.32M |
| OtherCurrentAssets | 1.13M | 1.03M | 1.33M | 796.00K |
| PrepaidAssets | 11.22M | 9.49M | 13.58M | 11.71M |
| Inventory | 39.23M | 39.70M | 24.75M | 19.33M |
| FinishedGoods | 903.00K | 583.00K | 1.48M | 4.54M |
| WorkInProcess | 36.62M | 37.38M | 21.06M | 12.57M |
| RawMaterials | 1.70M | 1.75M | 2.22M | 2.22M |
| Receivables | 36.54M | 24.09M | 13.48M | 15.41M |
| AccountsReceivable | 36.54M | 24.09M | 13.48M | 15.41M |
| CashCashEquivalentsAndShortTermInvestments | 358.48M | 350.49M | 389.39M | 466.08M |
| OtherShortTermInvestments | 275.04M | 301.61M | 295.22M | 234.18M |
| CashAndCashEquivalents | 83.43M | 48.88M | 94.17M | 231.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 44.11M | -34.18M | -79.82M | -159.19M |
| RepurchaseOfCapitalStock | -40.24M | 0.00 | 0.00 | |
| RepaymentOfDebt | -11.99M | -10.03M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 196.74M | |
| CapitalExpenditure | -281.00K | -718.00K | -292.00K | -1.50M |
| InterestPaidSupplementalData | 1.98M | 257.00K | ||
| IncomeTaxPaidSupplementalData | 2.18M | 496.00K | 1.98M | 257.00K |
| EndCashPosition | 83.43M | 48.88M | 94.17M | 231.90M |
| BeginningCashPosition | 48.88M | 94.17M | 231.90M | 272.35M |
| ChangesInCash | 34.56M | -45.30M | -137.73M | -40.45M |
| FinancingCashFlow | -49.09M | -5.13M | 2.43M | 221.11M |
| CashFlowFromContinuingFinancingActivities | -49.09M | -5.13M | 2.43M | 221.11M |
| NetOtherFinancingCharges | -6.13M | -2.28M | -1.04M | |
| ProceedsFromStockOptionExercised | 9.27M | 7.17M | 3.47M | 24.37M |
| NetCommonStockIssuance | -40.24M | 0.00 | 0.00 | 196.74M |
| CommonStockPayments | -40.24M | 0.00 | 0.00 | |
| CommonStockIssuance | 0.00 | 0.00 | 196.74M | |
| NetIssuancePaymentsOfDebt | -11.99M | -10.03M | 0.00 | 0.00 |
| NetLongTermDebtIssuance | -11.99M | -10.03M | 0.00 | 0.00 |
| LongTermDebtPayments | -11.99M | -10.03M | 0.00 | 0.00 |
| InvestingCashFlow | 39.26M | -6.71M | -60.63M | -103.87M |
| CashFlowFromContinuingInvestingActivities | 39.26M | -6.71M | -60.63M | -103.87M |
| NetOtherInvestingChanges | -43.00K | -11.86M | -663.00K | -17.84M |
| NetInvestmentPurchaseAndSale | 39.59M | 5.88M | -59.68M | -84.53M |
| SaleOfInvestment | 585.42M | 529.38M | 464.32M | 354.43M |
| PurchaseOfInvestment | -545.83M | -523.50M | -523.99M | -438.96M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -1.20M | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -1.20M | |
| NetPPEPurchaseAndSale | -281.00K | -718.00K | -292.00K | -303.00K |
| PurchaseOfPPE | -281.00K | -718.00K | -292.00K | -303.00K |
| CapitalExpenditureReported | 0.00 | -6.00K | ||
| OperatingCashFlow | 44.39M | -33.46M | -79.53M | -157.69M |
| CashFlowFromContinuingOperatingActivities | 44.39M | -33.46M | -79.53M | -157.69M |
| ChangeInWorkingCapital | 5.45M | -5.61M | -6.82M | -21.63M |
| ChangeInOtherWorkingCapital | 5.79M | 3.76M | 3.05M | |
| ChangeInOtherCurrentLiabilities | -750.00K | -673.00K | -652.00K | 332.00K |
| ChangeInOtherCurrentAssets | 31.00K | -16.00K | -363.00K | 353.00K |
| ChangeInPayablesAndAccruedExpense | 14.19M | 13.39M | 699.00K | 4.08M |
| ChangeInAccruedExpense | 13.33M | 12.15M | 1.49M | |
| ChangeInPayable | 860.00K | 1.24M | -792.00K | 4.08M |
| ChangeInAccountPayable | 860.00K | 1.24M | -792.00K | 4.08M |
| ChangeInPrepaidAssets | -1.83M | 4.40M | -2.40M | -5.33M |
| ChangeInInventory | 477.00K | -15.87M | -9.07M | -5.64M |
| ChangeInReceivables | -12.46M | -10.61M | 1.93M | -15.41M |
| ChangesInAccountReceivables | -12.46M | -10.61M | 1.93M | -15.41M |
| OtherNonCashItems | 788.00K | -1.51M | -1.61M | 10.00M |
| StockBasedCompensation | 31.60M | 45.31M | 32.30M | 31.24M |
| AssetImpairmentCharge | 0.00 | 916.00K | 3.65M | 245.00K |
| AmortizationOfSecurities | -12.73M | -12.14M | -1.57M | 660.00K |
| DepreciationAmortizationDepletion | 19.45M | 11.65M | 2.71M | 2.76M |
| DepreciationAndAmortization | 19.45M | 11.65M | 2.71M | 2.76M |
| AmortizationCashFlow | 2.10M | |||
| AmortizationOfIntangibles | 2.10M | |||
| Depreciation | 663.00K | |||
| OperatingGainsLosses | -5.91M | 5.95M | ||
| NetForeignCurrencyExchangeGainLoss | -5.91M | 5.95M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | 5.75M | -78.02M | -108.18M | -180.97M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AUPH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|